<?xml version='1.0' encoding='utf-8'?>
<document id="26519191"><sentence text="Use of Multiple Probes to Assess Transporter- and Cytochrome P450-Mediated Drug-Drug Interaction Potential of the Pangenotypic HCV NS5A Inhibitor Velpatasvir." /><sentence text="Velpatasvir (VEL; GS-5816) is a potent, pangenotypic hepatitis C virus (HCV), non-structural protein 5A inhibitor in clinical development for the treatment of chronic HCV infection"><entity charOffset="0-11" id="DDI-PubMed.26519191.s2.e0" text="Velpatasvir" /><entity charOffset="13-16" id="DDI-PubMed.26519191.s2.e1" text="VEL" /><entity charOffset="18-25" id="DDI-PubMed.26519191.s2.e2" text="GS-5816" /><pair ddi="false" e1="DDI-PubMed.26519191.s2.e0" e2="DDI-PubMed.26519191.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26519191.s2.e0" e2="DDI-PubMed.26519191.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26519191.s2.e0" e2="DDI-PubMed.26519191.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26519191.s2.e1" e2="DDI-PubMed.26519191.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26519191.s2.e1" e2="DDI-PubMed.26519191.s2.e2" /></sentence><sentence text=" In vitro studies indicate that VEL may inhibit several drug transporters and be a substrate for enzyme/drug transport systems in vivo"><entity charOffset="32-38" id="DDI-PubMed.26519191.s3.e0" text="VEL" /></sentence><sentence text=" The purpose of this study was to evaluate the potential of VEL as a perpetrator or victim of metabolic- and transporter-based drug-drug interactions using complementary probe drugs"><entity charOffset="60-62" id="DDI-PubMed.26519191.s4.e0" text="VEL" /></sentence><sentence text="" /><sentence text="This Phase 1 study was a randomized, cross-over, open-label, single- and multiple-dose, five-cohort study" /><sentence text=" Serial blood samples were collected following oral administration of reference and test treatments" /><sentence text=" The primary pharmacokinetic parameters of each analyte were compared when administered alone or in combination" /><sentence text=" The 90% confidence intervals (CI) for the ratio of the geometric least-squares means of the test and reference treatments was calculated for each analyte and parameter of interest" /><sentence text="" /><sentence text="This study demonstrated that VEL is a weak (P-gp, OATP) to moderate (breast cancer resistance protein) transport inhibitor"><entity charOffset="29-31" id="DDI-PubMed.26519191.s11.e0" text="VEL" /></sentence><sentence text=" As a victim of interactions, VEL is moderately affected by potent inhibitors and to a greater extent, potent inducers of enzyme/drug transporter systems"><entity charOffset="30-32" id="DDI-PubMed.26519191.s12.e0" text="VEL" /></sentence><sentence text="" /><sentence text="The impact of specific transporters and overall contribution of drug transport vs" /><sentence text=" metabolizing enzymes on the disposition of VEL was characterized through the use of complementary probes, despite the lack of phenotypic specificity, and informs a broad range of drug-drug interaction recommendations"><entity charOffset="44-46" id="DDI-PubMed.26519191.s15.e0" text="VEL" /></sentence><sentence text="" /></document>